Pipeline

Aurum's lead programme, ABL-101, is in the preperation stage for two Phase 2 clinical trials. Both trials build on the Phase 1 and Phase 2a human safety data accumulated across 43 patients and are designed to support regulatory submissions and licensing on the path to market authorisation.

Phase 2 Acute Stroke Trial — India

This trial is evaluating ABL-101's therapeutic effect, diagnostic capability, and safety profile in patients with acute ischaemic stroke. It is running with an established clinical research organisation with significant stroke trial experience at a leading Indian neurosciences centre. A successful outcome provides the clinical foundation for a Phase 2/3 trial and positions Aurum for accelerated market authorisation in India — a regulatory pathway with precedent, following the approval of Sovateltide for stroke following similarly sized trials. India represents Aurum's first and fastest route to market, with a stroke incidence of approximately 1.8 million cases per year.

Phase 2 Carotid Arteriosclerosis Imaging Trial — Switzerland

Approved by SwissMedic, this trial is assessing ABL-101's ability to visualise inflammation within atherosclerotic plaques — areas of arterial narrowing that carry a heightened risk of rupture and stroke. The trial uses fluorine-19 MRI in conjunction with ABL-101, and is being conducted in collaboration with researchers at the University of Lausanne. A positive result would support licensing of the inflammation imaging technology as a standalone commercial product, with a licensing target of 2028 — providing Aurum with a revenue stream ahead of full stroke market authorisation.

ABL-101's mechanism — delivering oxygen to tissue starved of it — is applicable across a wide range of serious conditions beyond stroke. Aurum is developing its pipeline across stroke, heart attack, traumatic brain injury, spinal cord injury and cardiac arrest, supported by pre-clinical and clinical collaborations in the UK, India, Switzerland, and the USA.

Route to Licence

Inflammation Diagnostic by 2029 and Stroke Market Authorisation by 2031